TRANSPOD
TransPod , the startup that is building the world’s leading ultra-high-speed ground transportation system (the TransPod Line ) to disrupt and redefine passenger and cargo transportation, unveiled the FluxJet, an industry-defining innovation that transforms the way we live, work, and travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005004/en/
Based on groundbreaking innovations in propulsion and fossil-fuel-free clean energy systems, the FluxJet is a fully electric vehicle that is effectively a hybrid between an aircraft and a train. Featuring technological leaps in contactless power transmission and a new field of physics called veillance flux , the FluxJet travels in a protected guideway at over 1000 km/h – faster than a jet and three times as fast as a high-speed train.
The FluxJet will operate exclusively on the TransPod Line, a network system with stations in key locations and major cities, featuring high-frequency departures designed to enable fast, affordable, and safe travel. Most recently, TransPod confirmed $550M US finance and announced the next phase of an $18B US infrastructure project to build the TransPod Line to connect the cities of Calgary and Edmonton in Alberta, Canada. Preliminary construction work, including the environmental impact assessment, has begun. This critical project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction. Once the TransPod Line is in operation, it will cost passengers approximately 44 per cent less than a plane ticket to travel the corridor and reduce CO2 emissions by 636,000 tonnes per year.
“All the hard work over the past few years has led to this milestone moment where talk is becoming a reality. The technology is proven, and we have the confidence of investors, governments, and partners to continue pushing forward to redefine transportation effectively,” said Sebastien Gendron, co-founder and CEO, TransPod.
At TransPod’s unveiling event in Toronto, a scaled-down FluxJet was featured in a live demonstration showing its flight capabilities. The almost 1-tonne FluxJet vehicle demonstrated a take-off, travel, and landing procedure within its guideway. Event and demo footage can be found here .
“This milestone is a major leap forward,” said Ryan Janzen, co-founder and CTO, TransPod. “The FluxJet is at a nexus of scientific research, industrial development, and massive infrastructure to address passengers' needs and reduce our dependence on fossil-fuel-heavy jets and highways.”
“TransPod completely changes the game with ultra high-speed, zero-emission passenger travel and freight transportation between major gateway cities,” said Yung Wu, CEO of MaRS Discovery District. “It is time for bold action from our policymakers, investors, and operators to support the commercialization of made-in-Canada innovations like TransPod, to win in the multi-trillion dollar global innovation economy."
“The FluxJet is a first for Canadian innovation and is the next great infrastructure project to be brought worldwide,” said Janzen. “The TransPod Line is being developed in collaboration with our partners in Europe, USA, and beyond, including universities, research centres, the aerospace industry, architecture, railway, and construction partners.”
TransPod’s FluxJet unveiling was made possible with the support and collaboration of the Building Trades of Alberta , Canada’s Building Trades Unions , Dassault Systèmes , DHL Express , MaRS , Ikos Consulting , REC Architecture , and SADE Engineering .
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada and has affiliate companies in Alberta, France, and the UAE. Visit www.transpod.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom